BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2816118
Number of visits today
238
Number of downloads
2065786
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Lasagna A, Zuccaro V, Sacchi P, Chiellino S, Bruno R, Pedrazzoli P. Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons? Future Oncol 2021;17:1577-80. [PMID: 33590770 DOI: 10.2217/fon-2020-1196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Lasagna A, Albi G, Maserati R, Zuccarini A, Quaccini M, Baldanti F, Sacchi P, Bruno R, Pedrazzoli P. Occult hepatitis B in patients with cancer during immunotherapy with or without chemotherapy: A real-life retrospective single-center cohort study. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1044098] [Reference Citation Analysis]
2 Lasagna A, Arlunno B, Imarisio I. A case report of pulmonary nocardiosis during pembrolizumab: the emerging challenge of the infections on immunotherapy. Immunotherapy 2022;14:1369-75. [PMID: 36420679 DOI: 10.2217/imt-2022-0152] [Reference Citation Analysis]
3 Maepa MB, Ely A, Kramvis A, Bloom K, Naidoo K, Simani OE, Maponga TG, Arbuthnot P. Hepatitis B Virus Research in South Africa. Viruses 2022;14:1939. [DOI: 10.3390/v14091939] [Reference Citation Analysis]
4 Lasagna A, Cassaniti I, Sacchi P, Baldanti F, Bruno R, Pedrazzoli P. Infectious complications and immunotherapy: old pitfalls and new horizons. Future Oncol 2022. [PMID: 35678614 DOI: 10.2217/fon-2022-0277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345